LAVA Therapeutics (LVTX) Competitors $1.55 -0.02 (-1.27%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.55 0.00 (0.00%) As of 09/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. LFVN, MEIP, NKTX, ELDN, SLN, HURA, CTOR, THTX, MOLN, and ALTSShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Lifevantage (LFVN), MEI Pharma (MEIP), Nkarta (NKTX), Eledon Pharmaceuticals (ELDN), Silence Therapeutics (SLN), TuHURA Biosciences (HURA), Citius Oncology (CTOR), Theratechnologies (THTX), Molecular Partners (MOLN), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Lifevantage MEI Pharma Nkarta Eledon Pharmaceuticals Silence Therapeutics TuHURA Biosciences Citius Oncology Theratechnologies Molecular Partners ALT5 Sigma LAVA Therapeutics (NASDAQ:LVTX) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Do analysts prefer LVTX or LFVN? LAVA Therapeutics currently has a consensus price target of $2.69, suggesting a potential upside of 73.23%. Lifevantage has a consensus price target of $30.50, suggesting a potential upside of 126.60%. Given Lifevantage's stronger consensus rating and higher probable upside, analysts plainly believe Lifevantage is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LVTX or LFVN more profitable? Lifevantage has a net margin of 4.12% compared to LAVA Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LAVA TherapeuticsN/A -106.29% -38.24% Lifevantage 4.12%34.67%15.24% Which has more risk & volatility, LVTX or LFVN? LAVA Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Does the media refer more to LVTX or LFVN? In the previous week, Lifevantage had 12 more articles in the media than LAVA Therapeutics. MarketBeat recorded 14 mentions for Lifevantage and 2 mentions for LAVA Therapeutics. Lifevantage's average media sentiment score of 0.54 beat LAVA Therapeutics' score of -0.50 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LAVA Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Lifevantage 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in LVTX or LFVN? 35.3% of Lifevantage shares are owned by institutional investors. 9.5% of LAVA Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, LVTX or LFVN? Lifevantage has higher revenue and earnings than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$11.98M3.40-$25.11M-$1.05-1.48Lifevantage$200.16M0.85$2.94M$0.6919.51 SummaryLifevantage beats LAVA Therapeutics on 14 of the 16 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.30M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.4820.8975.9926.43Price / Sales3.40458.96546.95119.09Price / CashN/A44.5237.0558.92Price / Book1.469.9310.916.06Net Income-$25.11M-$53.38M$3.29B$266.28M7 Day Performance-1.27%0.63%0.18%-0.32%1 Month Performance2.99%6.31%6.26%3.44%1 Year Performance-5.49%11.63%51.55%23.11% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics1.273 of 5 stars$1.55-1.3%$2.69+73.2%-4.9%$41.30M$11.98M-1.4860Short Interest ↑LFVNLifevantage4.3595 of 5 stars$12.84-0.4%$30.50+137.6%+53.3%$160.46M$200.16M18.47260News CoverageGap UpMEIPMEI Pharma0.973 of 5 stars$4.95-1.1%N/A+37.7%$160.07M$65.30M-1.04100News CoveragePositive NewsNKTXNkarta2.0119 of 5 stars$2.25+2.0%$13.60+505.8%-60.5%$159.45MN/A-1.52140ELDNEledon Pharmaceuticals1.7024 of 5 stars$2.65+2.9%$10.00+278.1%+1.2%$157.79MN/A-2.2510News CoverageAnalyst ForecastAnalyst RevisionSLNSilence Therapeutics1.9548 of 5 stars$5.21+2.9%$33.83+550.0%-72.8%$155.79M$27.17M-3.15100HURATuHURA Biosciences1.4005 of 5 stars$3.03+2.8%$12.67+317.6%N/A$152.40MN/A0.00N/ACTORCitius Oncology0.9581 of 5 stars$1.94+2.6%$3.00+54.6%+8.1%$152.04MN/A0.00N/ATHTXTheratechnologiesN/A$3.26+0.2%N/A+166.4%$149.67M$85.87M-17.13140Short Interest ↑MOLNMolecular Partners2.0197 of 5 stars$3.71-12.2%$12.00+223.9%-39.6%$149.61M$5.65M-1.93180Analyst ForecastGap DownHigh Trading VolumeALTSALT5 Sigma0.3949 of 5 stars$6.92+1.8%N/A+76.7%$149.22M$12.53M0.00170Options VolumeGap DownHigh Trading Volume Related Companies and Tools Related Companies Lifevantage Alternatives MEI Pharma Alternatives Nkarta Alternatives Eledon Pharmaceuticals Alternatives Silence Therapeutics Alternatives TuHURA Biosciences Alternatives Citius Oncology Alternatives Theratechnologies Alternatives Molecular Partners Alternatives ALT5 Sigma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LVTX Stock Alerts